Aetna · PSG In Lab · US health-plan appeal rights

PSG In Lab denied as duplicate or overlapping therapy by Aetna?

Q: How long do I have to appeal a Aetna PSG In Lab denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for psg in lab are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna Clinical Policy Bulletin (Polysomnography) + the applicable Clinical Policy Bulletin (CPAP) + the applicable Clinical Policy Bulletin (Narcolepsy)

The Aetna angle on PSG In Lab

## Why Aetna Denies In-Lab PSG as Duplicate Therapy

A duplicate-therapy denial for an in-laboratory polysomnography (PSG) typically occurs when Aetna's review system identifies that a prior sleep study — most commonly a home sleep apnea test (HSAT) — was already performed within a recent lookback period, or that an HSAT is authorized but has not yet been completed. The plan's policy may treat the in-lab PSG as redundant when a home study result is already available or pending, reflecting a coverage structure that establishes HSATs as the preferred initial diagnostic tool for most patients with suspected obstructive sleep apnea.

## Why This Denial Is Appealable

In-lab PSG and home sleep testing are not clinically equivalent for all patients. A home test measures a limited set of parameters and is considered inadequate for patients with certain comorbidities, high clinical suspicion for conditions other than obstructive sleep apnea, prior non-diagnostic or technically failed home studies, or clinical presentations where a full attended study is necessary to characterize the sleep disorder accurately. If the ordering clinician has documented a specific clinical reason why the in-lab study is necessary — rather than a preference — the duplicate-therapy label is contestable. Consult Aetna's published clinical policy for the conditions under which in-lab PSG is covered despite a prior home study.

## Federal Appeal Framework

Internal appeal: File within 180 days of the denial notice. Request Aetna's clinical policy for polysomnography and the specific criterion that was not met.
External review (ACA §2719): After internal denial, an accredited IRO reviews the medical evidence independently; its decision is binding on the plan.
ERISA §503: For employer-sponsored plans, the plan must disclose the criteria and any clinical guidelines relied upon.
Expedited review: Available if diagnostic delay would jeopardize the patient's health — document the clinical urgency in writing.
External review window: Initiate within four months of the final internal denial.

## Documentation to Gather

Prior sleep study results: Results of any prior HSAT or PSG, including technical quality assessment and any non-diagnostic findings.
Ordering physician's letter: A specific, individualized explanation of why the in-lab PSG is clinically necessary for this patient despite the prior study — tied to the patient's comorbidities, clinical presentation, and the limitations of home testing for this case.
Relevant medical history: Documentation of comorbidities, medications, and clinical findings that support the need for an attended, full-parameter study.
Applicable guideline organization reference: Cite the relevant professional society (such as the AASM) generically to support that in-lab PSG is within recognized clinical practice for this patient's profile.

## Criteria-Mapping Structure

Obtain Aetna's clinical policy for polysomnography. Identify the conditions under which in-lab PSG is covered following a prior home study. For each condition, document whether the patient's chart satisfies it — citing the specific document, date, and author. If the prior study was technically failed or non-diagnostic, make that the lead argument. A point-by-point response to the plan's own policy criteria is the most effective format for this appeal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna PSG In Lab

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.